Insider Selling: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Sells $18,636.80 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 1,664 shares of Atara Biotherapeutics stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $11.20, for a total transaction of $18,636.80. Following the transaction, the chief executive officer now directly owns 77,454 shares of the company’s stock, valued at approximately $867,484.80. This represents a 2.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Atara Biotherapeutics Trading Up 8.1 %

ATRA opened at $11.47 on Friday. The company has a market capitalization of $66.07 million, a price-to-earnings ratio of -0.44 and a beta of 0.50. Atara Biotherapeutics, Inc. has a 12-month low of $6.50 and a 12-month high of $39.50. The business’s fifty day simple moving average is $9.19 and its 200-day simple moving average is $10.11.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to analysts’ expectations of $23.00 million. During the same period last year, the business posted ($16.50) EPS. On average, equities research analysts predict that Atara Biotherapeutics, Inc. will post -12.12 EPS for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATRA. Geode Capital Management LLC raised its position in shares of Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 4,043 shares during the last quarter. State Street Corp increased its stake in Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares in the last quarter. Vestal Point Capital LP raised its holdings in shares of Atara Biotherapeutics by 11.3% in the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after buying an additional 12,677 shares during the last quarter. FMR LLC grew its holdings in shares of Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 7,381 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Atara Biotherapeutics in the 2nd quarter valued at $79,000. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ATRA has been the subject of several recent analyst reports. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. Canaccord Genuity Group boosted their price objective on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and decreased their target price for the stock from $25.00 to $18.00 in a research report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $16.67.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.